Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

BioAge Labs, Inc. BIOA NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
45/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$42.50
+156.5%

BioAge Labs, Inc. (BIOA) is a Biotechnology company in the Healthcare sector, currently trading at $16.57. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is BIOA = $43 (+156.5% upside).

Valuation: BIOA trades at a trailing Price-to-Earnings (P/E) of -7.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.54.

Financials: revenue is $9M, +0%/yr average growth. Net income is $81M (loss), growing at -28.5%/yr. Net profit margin is -896.1% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $6M against $272M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 14.24 (strong liquidity). Debt-to-assets is 1.9%. Total assets: $295M.

Analyst outlook: 2 / 3 analysts rate BIOA as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 52/100 (Partial), Future 73/100 (Pass), Income 10/100 (Fail).

$42.50
▲ 156.49% Upside
Average Price Target
Based on 3 Wall Street analysts offering 12-month price targets for BioAge Labs, Inc., the average price target is $42.50, with a high forecast of $62.00, and a low forecast of $23.00.
Highest Price Target
$62.00
Average Price Target
$42.50
Lowest Price Target
$23.00

BIOA SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 52/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BIOA

✓
VALUE Pass
100/100
BIOA trades at a trailing Price-to-Earnings (P/E) of -7.7 (S&P 500 average ~25). Forward PEG 0.54 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $43, implying +159.5% from the current price $17. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
BIOA: +0%/yr revenue is, -28.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet BIOA: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 14.24 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
52/100
BIOA: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 52/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
73/100
Analyst outlook: 2 / 3 analysts rate BIOA as buy (67%). Analyst consensus target is $43 (+159.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
BIOA: Net profit margin is -896.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range2.88-24
Volume314.21K
Avg Volume (30D)633.69K
Market Cap$596.19M
Beta (1Y)1.24
Share Statistics
EPS (TTM)-2.24
Shares Outstanding$35.93M
IPO Date2024-09-26
Employees62
CEOKristen Fortney
Financial Highlights & Ratios
Revenue (TTM)$9M
Gross Profit$9M
EBITDA$-92.78M
Net Income$-80.61M
Operating Income$-92.78M
Total Cash$281.1M
Total Debt$5.56M
Net Debt$-183.33M
Total Assets$294.89M
Price / Earnings (P/E)-7.4
Price / Sales (P/S)66.28
Analyst Forecast
1Y Price Target$42.50
Target High$62.00
Target Low$23.00
Upside+156.5%
Rating ConsensusBuy
Analysts Covering3
Buy 67% Hold 33% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS09077V1008

Price Chart

Track all markets on TradingView
BIOA
BioAge Labs, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
2.88 52WK RANGE 24.00

People Also View

ALLO
ALLO
Allogene Therapeutics, Inc.
$2.28
-25.37%
 CGC
CGC
Canopy Growth Corporation
$1.09
+0.93%
 AVIR
AVIR
Atea Pharmaceuticals, Inc.
$5.80
+1.58%
 EDIT
EDIT
Editas Medicine, Inc.
$3.39
+5.94%
 CABA
CABA
Cabaletta Bio, Inc.
$3.26
+1.88%
 OMI
OMI
Owens & Minor, Inc.
$2.68
+8.94%
 ACB
ACB
Aurora Cannabis Inc.
$3.53
+1.44%
 LFCR
LFCR
Lifecore Biomedical, Inc.
$5.20
+5.26%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message